Regulatory Compliance Sweep

Compliance Sweep, week of Aug 23, 2026

Published August 30, 2026 Coverage Aug 23, 2026 to Aug 29, 2026 Reviewed through Aug 29, 2026 Last modified Sep 5, 2026 Version 2
Correction, Sep 5, 2026, version 2Corrected stale executive-triage language and added the deferred AB 1778 federal scheduling trigger to the forward horizon. The original publication date above is unchanged.

Executive triage

Three actions this week: a federal rule corrected retroactively, a federal comment window that closes in three weeks, and a California home health agency licensure moratorium carrying two separate filing deadlines.

  • The federal independent dispute resolution final rule of June 4, 2026 was corrected on August 28, 2026 to restore omitted payment determination and binding determination text. The correction applies as of August 3, 2026, so disputes already in flight are governed by text that reads differently from the version originally published.
  • HHS opened docket HHS-OS-2026-0332 asking whether the routine, risk based, and shared clinical decision making categories used in federal vaccine recommendations should change. Comments close September 20, 2026.
  • The California Department of Public Health issued All Facilities Letter 26-28 on August 27, 2026, carrying Senate Bill 164 (Chapter 27, Statutes of 2026). A moratorium on home health agency licensure applies as of June 29, 2026. Applicants whose applications were pending on that date must respond by October 9, 2026 or CDPH withdraws the application automatically, and every currently licensed agency must file management personnel information on a one time basis no later than March 31, 2027.
  • The targeted official searches of the California Legislature and California enforcement authorities were completed for August 23 through August 29, 2026, and both source families are recorded as reviewed. AB 1778, which conforms the California controlled substance classification of testosterone to federal law, was reviewed and deferred to the forward regulatory horizon: it changes nothing today, because California reclassification happens only if the federal schedule becomes less restrictive. AB 1913 and SB 557 were reviewed and excluded as outside healthcare compliance scope. California enforcement activity for the week is carried in the Enforcement Intelligence Briefing. No California coverage gap is left open in this issue.
  • The forward horizon carries AB 1778's dormant California reclassification trigger tied to a future federal testosterone scheduling action, a still draft USCDI version 7, two Noridian MolDX open public meetings scheduled for October 2026, one of which carries a conflicting date on its own page, and whatever HHS does after the vaccine comment period closes.

Findings, highest priority first

Each card leads with priority, lifecycle, applicability, and deadline, then the detail.

P2 NEW Directly applicable Effective

Federal independent dispute resolution rule corrected, payment determination text restored and applied back to August 3

What changed
The Internal Revenue Service, the Employee Benefits Security Administration, the Centers for Medicare & Medicaid Services and the Office of Personnel Management issued a correcting amendment to the Federal Independent Dispute Resolution Operations final rule published June 4, 2026 at 91 FR 33900. The correction restores regulation text that had been omitted for payment determination procedures and for binding determinations, removes an inadvertently retained word, and repairs cross references across 26 CFR part 54, 29 CFR part 2590 and 45 CFR part 149. The correcting amendment is effective August 28, 2026 and applies as of August 3, 2026.
Why it matters
Hospitals and provider groups that run out of network payment disputes have been operating since August 3, 2026 against regulation text that did not say what the departments intended it to say. The restored payment determination and binding determination language is the operative text for disputes already in flight, so an internal procedure, a certified IDR entity submission template, or a vendor workflow built from the June 4 publication may cite paragraphs that no longer read the same way.
Response type
Validate
Confidence
High
Applies to
Health systems, Provider networks
Jurisdiction
Federal

Recommended actionPull the corrected sections of 45 CFR part 149 and compare them against the No Surprises Act dispute procedure, the offer and supporting information templates, and any vendor or outside counsel workflow. Confirm that submissions made on or after August 3, 2026 satisfy the restored text, note any that do not, and document the review and its date.

P2 NEW Directly applicable Effective compliance Oct 9, 2026

California imposes a home health agency licensure moratorium under Senate Bill 164, with pending applicant responses due October 9, 2026 and management personnel filings due March 31, 2027

What changed
The California Department of Public Health issued All Facilities Letter 26-28 on August 27, 2026, notifying home health agencies of the chaptering of Senate Bill 164 (Chapter 27, Statutes of 2026). SB 164 establishes a moratorium on home health agency licensure as of June 29, 2026, running until no later than 90 days after the effective date of the revised home health agency regulations CDPH is required to adopt. During the moratorium CDPH may not issue a new initial license or approve the addition of a branch office, and may grant an exception only on a written finding that the applicant has demonstrated unmet need for home health agency services in the proposed service area based on the concentration of existing services there. CDPH must stop processing applications for new licensure that had not been issued a license as of June 29, 2026. CDPH is writing to those applicants, who must either state an intent to withdraw or submit a justification and supporting documentation to the Centralized Applications Branch by October 9, 2026. CDPH withdraws the application automatically if neither is filed by that date. The bill also bars CDPH from approving a change of ownership within five years of the date a license was initially issued, with exceptions only for demonstrated continuity of care or for both financial hardship and unmet need. Separately, SB 164 requires each agency to have an administrator, an administrator designee, a director of patient care services, and a director of patient care services designee, and to submit for each a form HS 215A or successor form, a resume, and a list of all licensed facilities and home health agencies where that person currently serves as management personnel. Those submissions are due at initial application, within 10 business days of a change in management personnel, and, for currently licensed agencies, on a one time basis no later than March 31, 2027. An applicant for licensure of a private home health agency must submit fingerprints to the California Department of Justice for any person holding a 5 percent or greater interest in the corporation, partnership, or association that owns the agency. Grounds for denial, suspension, or revocation now also include prior Medicare or Medi-Cal termination or licensure suspension or revocation of an agency the applicant owned, operated, or managed, a demonstrated pattern and practice of state or federal violations in the last three years, presence on the HHS Office of Inspector General List of Excluded Individuals and Entities, failure of management personnel to cooperate with a CDPH inspection or complaint investigation, and failure to report a change in owner, management personnel, service area, or location.
Why it matters
The two dates in this letter belong to different owners and neither one covers the other. October 9, 2026 belongs to any organization with a home health agency licensure or change of ownership application pending as of June 29, 2026, because doing nothing by that date withdraws the application. March 31, 2027 belongs to every currently licensed agency, because the management personnel submission is a one time filing that applies whether or not anything changed. The expanded denial and revocation grounds also move exclusion list screening and management change reporting from a payer question to a state licensure question, and the five year change of ownership prohibition reaches transaction planning for any system that expected to acquire an existing home health agency license rather than apply for a new one.
Response type
Implement
Confidence
High
Applies to
Health systems, Provider networks
Jurisdiction
California

Recommended actionConfirm whether the organization holds a California home health agency license and whether any licensure or change of ownership application was pending as of June 29, 2026. For each pending application, decide before October 9, 2026 whether to withdraw or to file an unmet need justification with the Centralized Applications Branch, and document the decision and the date. For every current license, name an owner now for the one time management personnel submission due March 31, 2027 covering the administrator, the administrator designee, the director of patient care services, and that director's designee, and confirm the internal path for reporting a management personnel change meets the 10 business day requirement. Add the five year change of ownership prohibition to the transaction checklist. Confirm that exclusion list screening covers owners at the 5 percent threshold and management personnel, since a List of Excluded Individuals and Entities hit is now a stated ground for denial, suspension, or revocation.

P3 NEW Operationally relevant Announced comment Sep 20, 2026

HHS asks whether the federal vaccine recommendation categories should change, comments close September 20

What changed
The HHS Office of the Secretary published a request for information, docket HHS-OS-2026-0332, on the categories used in federal vaccine recommendations and the role of shared clinical decision making. It asks whether the routine or universal, risk based, and shared clinical decision making categories remain adequate and how recommendations should be established going forward. Comments are due September 20, 2026. The notice states that federal recommendations are recommendations and not mandates, and that the department believes the distinction should be preserved and made legible to the public.
Why it matters
Standing orders, immunization order sets, patient education material, quality measure workflows, and payer coverage arguments in many organizations are built on the routine versus shared clinical decision making distinction. The notice records that physicians report shared decision making recommendations take more time and create patient confusion, and that fewer than half of those surveyed knew those vaccines carry the same coverage requirement as routine ones. A change to the category framework would reach standing orders and coverage scripting well before it reaches a rule.
Response type
Comment
Confidence
High
Applies to
Health systems, Provider networks
Jurisdiction
Federal

Recommended actionInventory the standing orders, order sets, patient education pieces, and payer coverage scripts that reference a federal vaccine recommendation category. Decide by September 20, 2026 whether to comment, and keep the inventory so that a later category change can be traced to the documents it touches.

Forward regulatory horizon

What is coming, what triggers it, and what to do before it lands.

Final USCDI version 7 and the certification data set that follows it

Expected timing
No final version 7 as of this issue. Trade reporting on August 27, 2026 described a version 7 release, but the official ASTP interoperability standards page still lists version 6 of July 2025 as published and version 7 as a draft. Watch for a final version and a Standards Bulletin naming the certification timeline.
Applicability
Operationally relevant
Trigger
ASTP publishes a final United States Core Data for Interoperability version 7 and advances it through the Standards Version Advancement Process, which starts the update clock for certified health IT.
Prepare now
Confirm with the electronic health record vendor which USCDI version its certified modules meet today and what its stated roadmap is for version 6 and version 7, and record the answer with the date it was given.

Noridian MolDX open public meetings on proposed molecular coverage policies for Jurisdiction E

Expected timing
October 6, 2026 and October 13, 2026 as stated in the Noridian page titles. The October 13 page carries a conflict inside the source itself: its title and its registration deadline of October 12, 2026 both point to 2026, while the body text describes the meeting as taking place on October 13, 2025. The stated times are consistent across both, since 1pm to 3pm Central is the same as 2pm to 4pm Eastern, which points to a year typographical error in the body rather than a different meeting. Noridian has not corrected the page, so treat the October 13, 2026 date as unconfirmed pending correction or confirmation from Noridian. The October 6, 2026 page carries no such conflict, with its body meeting date and registration deadlines all in 2026.
Applicability
Directly applicable
Trigger
Noridian posts the proposed local coverage determinations and meeting materials for Jurisdiction E, which covers California, Hawaii, Nevada and the Pacific territories.
Prepare now
Identify which molecular and biomarker tests the organization orders, performs, or sends to a reference laboratory that fall inside the proposed policies, and decide whether to attend or submit comment. Before relying on the October 13 meeting date, confirm it directly with Noridian, because the page body and the page title do not agree on the year.

HHS action after the vaccine recommendation categories comment period closes

Expected timing
Comments close September 20, 2026. Any change to the category framework would follow, on no announced schedule.
Applicability
Operationally relevant
Trigger
HHS publishes a response, a revised category framework, or a proposed rule under docket HHS-OS-2026-0332.
Prepare now
Keep the standing order and patient education inventory built for the comment deadline so that a category change can be mapped to the affected documents without repeating the search.

California conforming reclassification of testosterone under new Health and Safety Code section 11056.5

Expected timing
No California date is set, and none can be set from the California side. Assembly Bill 1778 was approved by the Governor and chaptered on August 24, 2026, adding section 11056.5 to the Health and Safety Code, but the provision is conforming only: it operates when a federal scheduling action occurs and not before. Testosterone and dihydrotestosterone remain in federal Schedule III as of this issue, so the provision is dormant and there is no present operational change.
Applicability
Operationally relevant
Trigger
Testosterone or dihydrotestosterone is removed from federal Schedule III and placed in a less restrictive federal schedule, or is exempted under federal law. Only that federal action moves the California classification.
Prepare now
Monitor the federal controlled substance classification of testosterone and dihydrotestosterone, and take no operational step now, because nothing changes for prescribers, pharmacies, licensed facilities or CURES practice while the federal Schedule III classification stands. If the federal trigger occurs, assess which prescribing, pharmacy, controlled substance handling, CURES reporting, policy and system workflows the changed classification reaches.